Both SIRT3 and SIRT7 appear to function as tumour suppressors in the context of pancreatic cancer; low levels of both proteins were associated with more aggressive tumour phenotypes and poorer patient outcome. Here, SIRT7 is linked to pancreatic neoplasm.